Request allocation Contact 简体中文

Ethics & Bioresponsibility Council

Quarterly Meeting Summary

Date: 14 October 2026 Location: Hybrid (South San Francisco · Shenzhen · Geneva) Summary published: 21 October 2026

Members present

  • Dr. Lei Chen, Chief Scientific Officer — Chair
  • Dr. Corinne Aebischer, VP, Global Regulatory Affairs (Geneva, by video)
  • Yiran Tang, General Counsel & Corporate Secretary — Secretary to the Council
  • Dr. Helen Achterberg, VP, Food Safety & Quality
  • Dr. Yuting Zhou, VP, Research (Shenzhen)
  • Dr. Vera Ostrovskaya — External member (independent), by video

Quorum was confirmed.

In attendance for item 1

  • Dr. Stefan Hollmann, SVP, Manufacturing & Process Development

Agenda

  1. Review of Q3 program status
  2. Matters arising from prior minutes
  3. Scaffold disclosure language standardization
  4. Any new species concepts (none submitted)
  5. Confirmation of continued operations

1. Review of Q3 program status

The Council reviewed production performance at the Pingshan facility, sensory non-release rates, and partner feedback for the third quarter. Dr. Hollmann reported that production campaigns in the period performed within the expected window and that campaign duration remained within the 18–24-day range. Lots that met safety standards but were not released on sensory grounds were handled in accordance with existing chain-of-custody procedures.

Dr. Zhou reported that the Brachiosaurus program continues in development with no change to its scope as previously reviewed.

No programs were identified as requiring suspension.

2. Matters arising

Prior action on updating allergen-adjacent disclosure language: completed and verified on current packaging proofs.

3. Scaffold disclosure language standardization

The Council discussed the porcine scaffold disclosure on bone-in products. The Council endorsed treating the scaffold disclosure with equal prominence to major allergen statements, and endorsed the standard wording "Bone is scaffold only and is not derived from the cultivated species" for use across all bone-in SKUs and markets.

4. Any new species concepts

None submitted.

5. Confirmation of continued operations

Dr. Ostrovskaya noted that the current zoonotic risk profile remains consistent with prior assessments, given the absence of living animals or eggs at any stage of the company's processes.

The Council confirmed continued operations for all current programs.


Resolutions

  • No programs halted.
  • The current species pipeline remains limited to those previously reviewed.
  • Scaffold disclosure to be given equal prominence to major allergen statements on all bone-in SKUs.
  • Next meeting scheduled for January 2027.

Minutes approved for internal circulation and for publication of this summary.


The Ethics & Bioresponsibility Council reviews research programs against our Bioresponsibility Principles™ and reports to the Science & Bioresponsibility Committee of the Board. See Governance & Board. Summaries are circulated internally within five business days of each meeting.

Bringing the Taste of the Past, Tomorrow.